Hydrochloric Acid

Hydrochloric Acid

SCHEMBL19949271

Cl.N[C@@H](CC(=O)O)c1cc(F)cc(Br)c1

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 known ✓ P05106 1/20 0.32
DPP4 known ✓ P27487 1/20 0.32
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CTSA P10619 5/20 0.34
EEF2K O00418 1/20 0.34
GBA1 P04062 1/20 0.33
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33
ITGB1 P05556 1/20 0.32
ITGAV P06756 1/20 0.32
ITGA5 P08648 1/20 0.32
ITGB5 P18084 1/20 0.32
ITGB6 P18564 1/20 0.32
ITGB8 P26012 1/20 0.32
ITGA8 P53708 1/20 0.32
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
AKR1B1 P15121 1/20 0.31
GABBR2 O75899 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL19949272 1.00 KMT2A (0.37) KMT2ASMN1; SMN2CTSAEEF2KGBA1
SCHEMBL14698312 0.98 KMT2A (0.38) KMT2ASMN1; SMN2CTSAEEF2KGBA1
Hydrochloric Acid SCHEMBL19949273 0.88 KMT2A (0.41) KMT2ASMN1; SMN2CTSAIDO1TDO2
Hydrochloric Acid SCHEMBL19949274 0.88 KMT2A (0.41) KMT2ASMN1; SMN2CTSAIDO1TDO2
SCHEMBL19067137 0.86 KMT2A (0.42) KMT2ASMN1; SMN2CTSAGABBR2GABBR1
SCHEMBL7939349 0.86 EEF2K (0.42) KMT2ASMN1; SMN2CTSAEEF2KGBA1
SCHEMBL21314455 0.86 EEF2K (0.42) KMT2ASMN1; SMN2CTSAEEF2KGBA1
Hydrochloric Acid SCHEMBL19949396 0.84 KMT2A (0.37) KMT2ASMN1; SMN2CTSAITGB3ITGB1
Hydrochloric Acid SCHEMBL19949395 0.84 KMT2A (0.37) KMT2ASMN1; SMN2CTSAITGB3ITGB1
SCHEMBL19067190 0.82 KMT2A (0.38) KMT2ASMN1; SMN2CTSAITGB3ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3738953-A1 META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS WITH IMPROVED PHARMACOKINETIC PROPERTIES AND METHODS FOR THEIR MANUFACTURE Saint Louis University (US) 2020-11-18 EP disclosed
US-20200199079-A1 META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS UNIV SAINT LOUIS (US) 2020-06-25 US disclosed
EP-3294716-B1 META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS UNIV SAINT LOUIS (US) 2020-04-15 EP disclosed
US-10577330-B2 Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists SAINT LOUIS UNIVERSITY (US) 2020-03-03 US disclosed
US-20190023663-A1 META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS SAINT LOUIS UNIVERSITY 2019-01-24 US disclosed
US-10035778-B2 Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists SAINT LOUIS UNIVERSITY (US) 2018-07-31 US disclosed
US-20180072684-A1 META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS SAINT LOUIS UNIVERSITY 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10577330-B2 Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists ITGA2, ITGAL, ITGA5 ITGB3 17/4885DPP4 954/4885KMT2A 1302/4885
US-20190023663-A1 META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS ITGA2, ITGAL, ITGA5 ITGB3 17/4885DPP4 954/4885KMT2A 1302/4885
US-20200199079-A1 META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS ITGA2, ITGAL, ITGA5 ITGB3 17/4885DPP4 954/4885KMT2A 1302/4885
US-20180072684-A1 META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS ITGA2, ITGAL, ITGA5 ITGB3 17/4885DPP4 954/4885KMT2A 1302/4885
US-10035778-B2 Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists ITGA2, ITGAL, ITGA5 ITGB3 17/4885DPP4 954/4885KMT2A 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.